We are investigating Abiomed, Inc. (ABMD) (“Abiomed” or the “Company”) for potential violations of the federal securities laws.
On August 1, 2019, Abiomed announced its financial results for the first quarter of 2019. Among other results, Abiomed announced its third consecutive quarter of slowing revenue growth, and the Company’s full-year guidance expectations fell roughly $22 million short of market expectations. On this news, Abiomed’s stock price fell sharply on August 1, 2019.